Nivagen announced today that it has received FDA approval for its Sodium Bicarbonate products. Sodium Bicarbonate is the newest addition to Nivagen’s portfolio of generics and 505 B2 drugs. Nivagen’s approval will immediately help to address the current shortage of this product. With more than 22 molecules in the pipeline, Nivagen strives to bring more affordable medicines to US patients. Attached is a picture of the artwork.

Jay Shukla, CEO, emphasized, “Our dedication to innovation and affordability is clearly demonstrated through initiatives like this. With over 22 molecules in our development pipeline, we remain resolute in our mission to deliver more accessible medicines to patients.”

With the expanding portfolio and dedication to innovation, they aim to enhance accessibility to essential medications for patients nationwide.

For more information, please visit www.nivagen.com